한빛사 논문
Min-Hyun Baek, MD, PhD1; Eun Young Park, MS2,3; Hyeong In Ha, MD, PhD4; Sang-Yoon Park, MD, PhD5; Myong Cheol Lim, MD, PhD5,6,7; Christina Fotopoulou, MD, PhD8; and Robert E. Bristow, MD, PhD9
1Department of Obstetrics and Gynecology, Hallym University Sacred Heart Hospital, Anyang, Korea
2Biostatistics Collaboration Team, Research Core Center, National Cancer Center, Goyang, South Korea
3Department of Statistics and Data Science, Yonsei University, Seoul, South Korea
4Department of Obstetrics and Gynecology, Pusan National University Yangsan Hospital, Pusan, South Korea
5Center for Gynecologic Cancer and Center for Clinical Trials, National Cancer Center, Goyang, South Korea
6Rare & Pediatric Cancer Branch and Immuno-oncology Branch, Division of Rare and Refractory Cancer, Research Institute, National Cancer Center, Goyang, South Korea
7Graduate School of Cancer Science and Policy, National Cancer Center, Goyang, South Korea
8Department of Gynecologic Oncology, Imperial College London, London, United Kingdom
9Division of Gynecologic Oncology, Obstetrics and Gynecology, Irvine Medical Center, University of California, Orange, CA
*M.-H.B. and E.Y.P. have equally contributed to this work.
*C.F. and R.E.B. have equally contributed to this study as cosenior authors.
Abstract
PURPOSE
The survival impact of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer was studied.
METHODS
We identified published studies from 1983 to 2021 following our inclusion criteria from MEDLINE, EMBASE, and Cochrane library. To integrate the effect size of single-arm studies, meta-analysis was performed using death rate as a primary outcome. The effect of complete cytoreduction and optimal cytoreduction on survival was evaluated using meta-regression. The pooled death rate was presented with a 95% CI. The publication bias was evaluated with the funnel plot and Egger's test, and sensitivity analysis was performed. To overcome missing death rates, the linear regression model was performed on log-transformed median overall survival (OS) time using study size as a weight.
RESULTS
Thirty-six studies with 2,805 patients reporting death rates were used for this meta-analysis of the 80 eligible studies. There was strong heterogeneity, with the P value of the Cochrane Q test of < 0.0001 and Higgins's I2 statistics of 86%; thus, we considered a random effect model. The pooled death rate was 44.2% (95% CI, 39.0 to 49.5), and both the complete and optimal cytoreductions were associated with better survival outcomes as significant moderators in the meta-regression model (P < .001 and P = .005, respectively). Although 14 studies were located outside the funnel plot, Egger's test indicated no publication bias (P = .327). A sensitivity analysis excluding 14 studies showed similar results. In the linear regression model on the basis of 57 studies, the median OS time increased by 8.97% and 7.04% when the complete and optimal cytoreduction proportion increased by 10%, respectively, after adjusting other variables.
CONCLUSION
Secondary cytoreductive surgery, resulting in maximal tumor resection, significantly prolongs OS in platinum-sensitive recurrent ovarian cancer.
논문정보
관련 링크
연구자 키워드
연구자 ID
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기